In this video, InMed Pharmaceuticals’ CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat serious diseases with high unmet needs. InMed is the first company to advance CBN into clinical trials for therapeutic development. Mr. Adams also provides an update on the company’s programs in epidermolysis bullosa (EB) and glaucoma and its biosynthesis platform.
InMed’s CEO Eric A. Adams presents at Edison Open House: Global Healthcare 2021
InMed Pharmaceuticals CEO, Eric A. Adams, is interviewed by Science Journalist and Broadcaster Vivienne Parry Obe at the Edison Open House: Global Healthcare Conference 2021.